Mainstay treatments are renin-angiotensin-aldosterone system inhibitors, mineralocorticosteroid antagonists and -blockers, and, as mentioned earlier, SGLT-2 inhibitors, especially in people with comorbid diabetes
These stacks aim to explore synergies between complementary pathways
They are also discreet, easy to transport and can be incorporated into a daily routine of a research subject more easily than other methods of peptide administration, as they dont require sterile environments or reconstitution
In contrast, HGH is a controlled substance, and its use is highly regulated
In Phase 2 trials, treatment with survodutide led to greater reductions in both HbA1c levels and body weight compared to placebo after 16 weeks